AKT1 and Epstein-Barr virus infection: Taken together, in real-world GC cases accompanied by EBV infection or ARID1A mutation in cooperation with PIK3CA mutation, the type 2 immune microenvironment and PI3K/AKT activation are likely to be conserved and may be potential therapeutic targets.